Clinical Trial Update: Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of a peptide vaccine to prevent recurrence of nasopharyngeal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• Peptide vaccine for nasopharyngeal cancer (peptide vaccine)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Nasopharyngeal Neoplasms | Phase 1 | Status: COMPLETED